Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea
Executive Summary
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
You may also be interested in...
Celltrion Sees Double-Digit Growth In Sales And Profit
South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.